Evaluation of ST2 and NT-proBNP as cardiac biomarkers in dogs with heartworm disease = Evaluation of ST2 and NT-proBNP as cardiac biomarkers in dogs with heartworm disease

다국어 초록 (Multilingual Abstract)

This study compared serum concentrations of suppression of tumorigenicity 2 (ST2) and N-terminal pro-B-type natriuretic peptide (NT-proBNP) between healthy and heartworm- infected dogs. Eighteen heartworm-infected dogs and five healthy dogs were included in the study. Dogs were diagnosed and categorized by history, clinical signs, and blood assay, thoracic radiography, echocardiography, and commercial ELISA kit results. Serum samples were sent to the IDEXX reference laboratory for NT-proBNP measurement. ST2 was examined by using a canine interleukin 33 receptor ELISA kit with the quantitative sandwich ELISA method. The severely infected group showed significant elevation of NT-proBNP concentration over those of the control (P=0.03) and mildly infected (P=0.04) group. There were no significant difference in ST2 concentrations among the three groups. The usefulness of NT-proBNP as a cardiac biomarker in dogs with severe heartworm disease was confirmed by the results of this study. Further investigations to assess ST2 as a cardiac biomarker are warranted.

참고문헌 (Reference)

1 Kelihan HB, "Weekly variability of plasma and serum NT-proBNP measurements in normal dogs" 11 : S93-S97, 2009

2 Villacorta H, "Soluble ST2 testing: a promising biomarker in the management of heart failure" 106 : 145-152, 2016

3 Song KH, "Serological update and molecular characterization of Dirofilaria im- mitis in dogs, South Korea" 88 : 467-469, 2010

4 Shah RV, "ST2: a novel remodeling biomarker in acute and chronic heart failure" 7 : 9-14, 2010

5 American heartworm society, "Guidelines for the diagnosis, prevention and management of heartworm (Dirofilaria immitis) infection in dogs"

6 Ettinger SJ, "Evaluation of plasma N-terminal pro-B-type natriuretic peptide concentrations in dogs with and without cardiac disease" 240 : 171-180, 2012

7 Schmidt MK, "Effect of azotemia on serum N-terminal proBNP concentration in dogs with normal cardiac function: a pilot study" 11 : S81-S86, 2009

8 Carreton E, "Dirofilaria immitis infection in dogs: Cardiopulmonary biomarker levels" 176 : 313-316, 2011

9 Bayes-Genis A, "Combined use of high‐sensitivity ST2 and NTproBNP to improve the prediction of death in heart failure" 14 : 32-38, 2012

10 Oyama MA, "Clinical utility of serum N-terminal pro-B-type natriuretic peptide concentration for identifying cardiac disease in dogs and assessing disease severity" 232 : 1496-1503, 2008

11 Ebisawa T, "Clinical use of n-terminal pro-brain natriuretic peptide concentrations for assessing the severity and prognosis of myxomatous mitral valve disease in dogs" 10 : 234-242, 2012

12 Di Sacco B, "Clinical classification of heartworm disease for the purpose of adding objectivity to the assessment of therapeutic efficacy of adulticidal drugs in the field" American Heartworm Society 209-214, 1992

13 Carreton E, "Cardiopulmonary and in- flammatory biomarkers in the assessment of the severity of canine dirofilariasis" 206 : 43-47, 2014

14 Braunwald E, "Biomarkers in heart failure" 358 : 2148-2159, 2008

15 Boswood A, "Biomarkers in cardiovascular disease: Beyond natriuretic peptides" 11 : S23-S32, 2009

16 Atkinson AJ, "Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework" 69 : 89-95, 2001

17 Piper S, "Biologic variability of soluble ST2 in patients with stable chronic heart failure and implications for monitoring" 118 : 95-98, 2016

18 Ruaux C, "Biologic variability in NT-proBNP and cardiac troponin-I in healthy dogs and dogs with mitral valve degeneration" 44 : 420-430, 2015